A patient complaint about a cosmetic injectable rarely stays confined to the injection itself. It can expose the clinic's prescribing arrangements, the qualifications of the person who administered the product, the consent discussion, the handling of complications and the advertising that brought the patient through the door.

For cosmetic clinic owners, doctors and nurses, the commercial consequences can be immediate. A request for records may develop into an investigation. A practitioner may face restrictions before the complaint is finally determined. The business may need to change how it operates while several regulators examine different parts of the same treatment.

The first question is not simply, “Did the treatment go wrong?” It is, “Which obligations apply, what does the evidence show, and what must we do now?” This guide focuses on non-surgical cosmetic clinics in NSW, including injectables, and the practical response to regulatory scrutiny. It distinguishes professional standards from medicines law, advertising restrictions and the separate responsibilities of the clinic and its practitioners.

01 Why Cosmetic Clinic Systems Are Under Scrutiny

Recent enforcement illustrates two different risks. On 19 October 2026, Ahpra reported that a Victorian woman who falsely presented herself as a registered nurse and provided a cosmetic injectable treatment had been convicted and ordered to perform 150 hours of community work. Ahpra said she had used another practitioner's identity. The patient, herself a qualified nurse, became concerned about the treatment and complained after experiencing significant bruising.

This was a prosecution for false professional representations, not a disciplinary decision against a genuine registered nurse. Its practical lesson for employers is nevertheless clear: verify identity and registration independently. Do not rely only on a certificate, a social-media biography or a registration number supplied by an applicant. Check the public register, match the person to the entry and examine applicable conditions.

A separate April 2026 announcement concerned Siena Beauty Pty Ltd, a Western Australian practice management company. Ahpra reported that the company pleaded guilty to failing to comply with a Schedule 5 Notice to Produce Information, despite extensions. It was fined $2,500 and ordered to pay $5,000 towards legal costs. Ahpra described this as its first prosecution for that offence under the National Law. The underlying investigation concerned a practitioner's use of supplements, alternative treatments and devices; it should not be represented as a cosmetic-injectables prosecution.

The significance for clinic owners is the reach of information-gathering powers. Incorporating the business or engaging practitioners as contractors does not necessarily place the company's records beyond a regulator's reach.

A clinic can face scrutiny of its business systems even when the original complaint concerns an individual practitioner.

02 Ahpra, Not APRA: Identify the Rules and the Regulator

Ahpra is the Australian Health Practitioner Regulation Agency. APRA is the Australian Prudential Regulation Authority and is not the regulator of health-practitioner registration. For cosmetic clinics, Ahpra and the relevant National Boards form part of the regulatory picture, but NSW has important co-regulatory arrangements.

The clinical guidelines effective from 2 September 2025 apply to registered health practitioners performing non-surgical cosmetic procedures, except medical practitioners. Doctors instead have the Medical Board of Australia's guidelines for cosmetic surgery and procedures, effective from 1 July 2023. The doctor's non-surgical obligations must be read in the correct section, not borrowed from the cosmetic-surgery requirements.

The 2025 guidelines do not confer authority to perform injectables or expand a profession's scope of practice. They operate alongside professional competence requirements, medicines law and other obligations. Approved guidelines can be evidence of appropriate professional conduct or practice under section 41 of the National Law. A departure may require explanation and can support regulatory action; it is not automatically a separate criminal offence merely because it breaches a guideline.

In NSW, the Health Care Complaints Commission (HCCC) and the relevant professional council regulate registered practitioners together. The HCCC assesses complaints and also has responsibilities concerning health-service organisations and non-registered providers. A doctor may deal with the Medical Council of NSW; a nurse may deal with the Nursing and Midwifery Council of NSW. These councils are distinct from the national Medical Board and Nursing and Midwifery Board.

The Therapeutic Goods Administration (TGA) may examine therapeutic-goods advertising and product supply issues. NSW Health administers relevant state medicines requirements. A complaint can therefore involve overlapping pathways, not one consolidated “Ahpra case”. Identify who is being asked to respond, under which power and to which allegations.

03 Prescribing and Administration: A Prescription Is Not the Whole Answer

A common regulatory vulnerability is the gap between a clinic's documented process and what actually occurs. An online questionnaire may capture medical information, but it is not a substitute for a required real-time prescribing consultation. A prescription in the file does not establish that the prescriber assessed that particular patient.

For practitioners covered by the 2025 clinical guidelines, cosmetic-injectable prescribing requires an in-person or video consultation each time the injectable is prescribed. Asynchronous prescribing by text, email or an online equivalent is not acceptable. Each patient requires an individual prescription; bulk or batch prescribing is not acceptable. Doctors must separately comply with their Medical Board obligations and applicable medicines law.

NSW Health's explanation of the cosmetic-medicines rules commencing on 1 September 2021 identifies restrictions on administration, patient review, directions, storage, record keeping and business risk management. For the additional restrictions described in that guidance, administration is limited to an authorised practitioner or a nurse acting under the direction of a medical practitioner or nurse practitioner. The directing medical or nurse practitioner must personally review the patient, including by audiovisual link where permitted.

The guidance identifies important exceptions: those additional restrictions do not apply where an authorised practitioner personally administers the medicine, or where a hospital employee administers it under an authorised practitioner's direction. “Authorised practitioner” includes a dentist as well as a medical practitioner or nurse practitioner. These exceptions do not remove other applicable medicines, competence or professional obligations. Check the actual arrangement and legal provisions rather than assuming every setting follows the same pathway.

Separate three questions: who may prescribe, who may administer, and who has the competence to perform the treatment safely? A short training course does not, by itself, establish all three. Nor does the business label “nurse injector”. A nurse's scope, competence, professional obligations and the lawful prescribing or direction arrangements require their own assessment.

  • Can the clinic show the patient's individual consultation and assessment?
  • Can it identify the prescriber, the treating practitioner and the direction or prescription relied upon?
  • Do the records identify the treatment, product, quantity and relevant batch information?
  • Are lawful supply, storage, emergency arrangements and follow-up supported by evidence?
  • Do practice arrangements comply with any registration conditions?

These are practical audit questions, not a substitute for checking every statutory requirement. Where the workflow is unsafe or potentially unlawful, address that risk immediately. Do not retrospectively create consultation notes suggesting that an assessment occurred when it did not.

05 Social Media: Two Different Advertising Risks

A cosmetic clinic's website and social accounts can attract scrutiny separately from its clinical work. The first issue is advertising a regulated health service under the National Law. The second is advertising therapeutic goods, including prescription-only medicines, under the therapeutic-goods framework.

The higher-risk non-surgical cosmetic-procedure advertising guidelines effective from 2 September 2025 apply to people and businesses advertising those procedures when performed by registered health practitioners. The obligations are not confined to the treating practitioner. Outsourcing content to an agency or influencer does not remove the advertiser's responsibility.

Review misleading claims, unrealistic expectations, inducements, testimonials, patient imagery and influencer content. Do not assume every independently posted patient review is an advertisement controlled by the clinic. However, resharing endorsements, using them in promotional material or interacting with positive reviews can create testimonial issues under the guidelines. Before-and-after photographs are not all categorically prohibited, but consent, accuracy, presentation and the full advertising context matter.

Removing a product name may not solve a TGA problem

The TGA's March 2024 announcement explained that it no longer permitted references such as “wrinkle reducing injections” where a reasonable consumer would understand the content as promoting the use or supply of a prescription medicine. Its cosmetic-injections FAQ, updated in July 2026, expressly states that the legislation concerning cosmetic injectables had not changed. That distinction matters: guidance about advertising interpretation is not the same as a newly enacted ban.

The TGA generally distinguishes promotion of a health service from promotion of therapeutic goods. Whether content crosses that line depends on the message and context, not just whether the brand name appears. An advertisement can therefore remain problematic after a clinic replaces a medicine name with a generic treatment description.

Audit the entire customer journey: captions, videos, hashtags, booking descriptions, price lists, paid promotions, linked pages and influencer arrangements. Preserve existing content before making necessary compliance changes so there is an accurate record of what was published. Do not use a patient complaint as an occasion to delete evidence.

06 Restrictions Can Arrive Before a Final Decision

A complaint is not a finding of misconduct. Nevertheless, a regulator may have protective powers that operate before final disciplinary proceedings. In NSW, section 150 of the National Law (NSW) permits relevant councils to impose conditions or suspend registration as a temporary protective measure in the circumstances specified by the law.

The Health Professional Councils Authority explains that the practitioner must comply immediately with suspension or conditions, even if they intend to seek review or appeal. Do not assume that lodging a challenge automatically stays the restriction. The available review, appeal and any stay application require separate attention to the applicable procedure and deadline.

For a clinic, conditions may affect rosters, supervision, prescribing and the treatments that can be offered. Continuing the same service through a nominally different arrangement may not satisfy the restriction. Read its actual terms before deciding how the business can continue operating.

Registration restrictions are also different from prohibition orders affecting non-registered providers. The HCCC records a permanent prohibition order concerning non-registered cosmetic-injectables provider Norsafiza Binti Zakaria, effective from 24 March 2025. The order restricts health-service provision and promotion of the services covered by it. This demonstrates a separate enforcement mechanism; it should not be treated as a disciplinary finding about registered nurse-led clinics generally.

If immediate action is proposed, a useful response addresses the actual identified risk with evidence. Training certificates alone may not answer concerns about prescribing, patient assessment or emergency care. Explain which activities have stopped, what safeguards have been implemented and how those safeguards can be verified, while responding carefully to disputed allegations.

07 Your First Response to a Complaint or Notice

The following are practical risk-management steps. Their application depends on the facts and the particular notice, rather than one universal statutory timetable.

  1. Protect the patient first. Arrange appropriate clinical review or emergency referral and stop any unsafe practice. Do not wait for the investigation to conclude before addressing a current safety risk.
  2. Identify the respondent and the power. Is the letter directed to the practitioner, prescriber, employer or operating company? Is it a request for an explanation, a compulsory production notice or notice of proposed restrictions?
  3. Notify the insurer promptly. Check the policy's notification and cooperation requirements before agreeing to admissions, settlements or representation arrangements. The clinic and its practitioners may have conflicting interests.
  4. Preserve the full evidence. Retain clinical notes, prescriptions, consent versions, images, product and batch records, communications, incident reports and advertising. Suspend routine deletion where relevant.
  5. Use the actual deadline. Diarise the date in the notice. Request an extension early if needed and obtain confirmation. The HCCC's approximately 60-day complaint-assessment period is not a universal deadline for your response.
  6. Address each allegation directly. Separate established facts, disputed facts, clinical reasoning and genuine remediation. Use a chronology and source records where helpful. Avoid speculation or criticism of the complainant.
  7. Check production, privacy and privilege. The HCCC identifies compulsory information and records powers under sections 21A and 34A of the Health Care Complaints Act 1993 (NSW). Do not assume privacy permits a blanket refusal. Obtain advice about the particular power and any valid privilege claim; an internal review is not automatically legally privileged.
  8. Understand disclosure and restrictions. HCCC guidance says responses ordinarily go to the complainant unless assessment-only use is expressly requested. Such a request is not a guarantee against every later lawful disclosure. Comply with any existing conditions while considering challenge rights.

Also assess whether a mandatory notification obligation arises. An adverse outcome or a dissatisfied patient does not automatically meet the threshold. The notifier's role, reasonable belief and category of notifiable conduct matter. HCCC guidance warns that complaining directly to the Commission does not itself discharge an applicable obligation to notify Ahpra under the National Law.

A good response is accurate, evidence-based and directed to the regulator's concerns. It protects patient safety without conceding allegations that the evidence does not establish.

08 Prepare for the NSW Medicines Transition and Seek Advice Early

A further NSW medicines-law transition is scheduled for 5 November 2026. NSW Health states that the Poisons and Therapeutic Goods Act 1966 and its Regulation will be replaced by the Medicines, Poisons and Therapeutic Goods Act 2022 and the Medicines, Poisons and Therapeutic Goods Regulation 2026. Its cosmetic-use-substances guidance expressly describes requirements applying from that date onwards.

As at 19 October 2026, those forthcoming requirements should not be described as already operative. Clinics should use the published guidance to review directions, administration, records, storage and business responsibilities before commencement. Historical conduct must be assessed under the law applicable at the relevant time, with any transition provisions considered.

GopherWood Lawyers acts in regulatory disputes and investigations. For a cosmetic clinic facing a complaint, a production notice, proposed registration restrictions or advertising scrutiny, early advice can help identify the legal issues, organise the evidence and prepare the response. Where clinical issues require independent professional input, those issues should be assessed by an appropriately qualified practitioner.

Contact GopherWood Lawyers about a cosmetic-clinic regulatory issue, or read more about our Regulatory Disputes & Investigations practice.

This article addresses non-surgical cosmetic-clinic regulation with a NSW focus and reflects official material reviewed on 19 October 2026. It is general information, not medical advice or legal advice on a particular matter. Professional requirements, medicines laws and complaint pathways differ between jurisdictions and may change.

Official sources and further reading
Become a Client